News

Celcuity Showcases Promising Phase 3 Data at ESMO Congress

Celcuity Showcases Promising Phase 3 Data at ESMO Congress

Celcuity's Presentation of VIKTORIA-1 Trial Results

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company dedicated to developing targeted oncology therapies, is thrilled to announce its participation at the significant European Society of Medical Oncology (ESMO) Congress. During this esteemed event, Celcuity will share groundbreaking findings from its pivotal Phase 3 VIKTORIA-1 trial.

Details of the Late Breaking Oral Presentation

This important presentation, focusing on the PIK3CA wild-type cohort of the VIKTORIA-1 trial, is scheduled for October 18, 2025. Attendees can expect in-depth insights regarding the efficacy and safety of the innovative combination therapy involving gedatolisib.

Presentation Title and Timing

The oral presentation is titled:
Gedatolisib + fulvestrant ± palbociclib vs fulvestrant in patients with HR+/HER2-/PIK3CA wild-type advanced breast cancer: First results from VIKTORIA-1
Abstract Number: 3535
Session Title: Proffered paper session 1: Breast Cancer, metastatic
Date: October 18, 2025
Time: 10:15 am – 11:45 am CEST

Significance of the VIKTORIA-1 Trial

The VIKTORIA-1 trial is crucial as it evaluates the effectiveness of gedatolisib, a potent pan-PI3K and mTORC1/2 inhibitor, used in conjunction with fulvestrant and optional palbociclib for patients dealing with HR+/HER2- advanced breast cancer. By comprehensively targeting the PAM pathway, gedatolisib presents a noteworthy advancement compared to other treatments that only address PI3K?, AKT, or mTORC1 individually. The trial has already concluded enrollment for the PIK3CA wild-type cohort, yet continues to seek participants for the PIK3CA mutant cohort, marking a pivotal moment in breast cancer treatment research.

Further Expansions in Clinical Research

Moreover, Celcuity is not stopping at VIKTORIA-1. The company is actively conducting additional studies, such as the Phase 1/2 CELC-G-201 trial, which investigates the combination of gedatolisib and darolutamide in patients with metastatic castration-resistant prostate cancer. Another trial, the VIKTORIA-2 study, aims to assess the potential of gedatolisib combined with a CDK4/6 inhibitor and fulvestrant as a first-line treatment for HR+/HER2- advanced breast cancer.

About Celcuity: Innovations in Cancer Treatment

Celcuity Inc. prioritizes developing targeted therapies to enhance the lives of cancer patients. With a robust pipeline centered around the unique properties of gedatolisib, Celcuity strives to meet the pressing needs of patients battling various solid tumors. Their commitment to research and development is driven by a passion for unearthing innovative solutions in the oncology space. For more information, you can visit www.celcuity.com.

Frequently Asked Questions

What is the VIKTORIA-1 trial?

The VIKTORIA-1 trial evaluates the combination of gedatolisib and fulvestrant in treating patients with HR+/HER2- advanced breast cancer.

When will the results from the VIKTORIA-1 trial be presented?

The results will be presented on October 18, 2025, during a session at the ESMO Congress.

What is gedatolisib?

Gedatolisib is a novel pan-PI3K and mTORC1/2 inhibitor that targets the PAM pathway, differentiating itself from other therapies.

What are the implications of the VIKTORIA-1 trial?

This trial could provide critical insights into the efficacy of gedatolisib combined with fulvestrant for treating advanced breast cancer.

How can I learn more about Celcuity's trials?

Further details regarding Celcuity’s ongoing clinical trials can be found on their website at www.celcuity.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

NYSE Reflects on 9/11: Honoring Lives and Legacy

Updated Category News Views 7

A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 6

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
Oil Markets Shift Focus: Pipelines Trump Drilling

Updated Category News Views 9

Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...

Continue Reading
Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 5

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
Lick the Plate Hits 2,000 Shows with Clown Band

Updated Category News Views 5

They say good things come in bizarre packages, and that's exactly the case as David Boylan's Lick the Plate zany celebration marks 15 years on air with its 2,000th episode. If you think of radio as a predictable endeavor, well, you're not tuned into Lick the Plate. A Milepost Draped in Multicolored Fabrics When you're browsing through colorful avenues of radio fame, it's...

Continue Reading
Jari Spirits Set to Shake Up U.S. Market After Big Wins

Updated Category News Views 4

Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...

Continue Reading
QuickFi Nabs Top Finovate Award for Fourth Time

Updated Category News Views 5

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Continue Reading
Streamlined AI Video Analytics for Public Safety Unveiled

Updated Category News Views 4

AI Without the Headache Alright folks, IREX is shaking things up, and not in the usual iterative, bit-by-bit tech progression way. StreamVLM™ has been rolled out as the world's first vision-language model (VLM) analytics engine tailored for the public safety sector—specifically, for cloud platforms. I’ve been around the block enough times to spot a significant shift...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 14

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
Supply Maverick Simplifies Global Shipping Processes

Updated Category News Views 5

Paving the Way for Seamless International Shipping Supply Maverick's got a new mantra, folks: simplicity. They're slicing through the mess of international shipping and bringing some much-needed clarity for customers in Canada, Australia, and New Zealand. It’s about time someone shook up the logistics playbook. The Nuts and Bolts of the New Shipping System Imagine being...

Continue Reading

Top 5 Most Recently Viewed Articles

Class Action Lawsuit Alert for Fortrea Holdings Inc. Investors

Updated Category News Views 147

Attention Fortrea Holdings Inc. Investors The Gross Law Firm has issued an important notice targeting shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). This notice serves as a call to action for those who purchased shares during the class action period outlined below. Why This Matters for Shareholders If you are a shareholder who has acquired shares of FTRE during the...

Continue Reading
Embracing Life's Trials: A Memoir of Resilience and Hope

Updated Category News Views 247

Embracing Life's Trials: A Memoir of Resilience and Hope Liberty Hill Publishing has unveiled a powerful memoir that resonates deeply with anyone who has faced struggles related to autism, mental health issues, and other significant life challenges. This poignant book by author Michael Beck provides insight into the complexities of living with autism and grappling with...

Continue Reading
Primo Brands Faces Class Action Amid Major Integration Issues

Updated Category News Views 272

Primo Brands Faces Legal Challenges Over Integration Failures Investors in Primo Brands Corporation (NYSE: PRMB) are currently facing a significant challenge as they navigate the implications of a class action lawsuit. This comes after serious doubts were raised regarding a botched merger that has led to major operational issues within the company. Legal representatives...

Continue Reading
McCormick's Quarterly Dividend Announcement and Company Insights

Updated Category News Views 283

McCormick's Dividend Declaration: A Sign of Stability The board of directors at McCormick & Company, Incorporated (NYSE: MKC) has taken an important step by declaring a quarterly dividend of $0.45 per share on its common stock. This commitment reflects the company’s continued dedication to providing value to its shareholders and signifies a stable financial performance...

Continue Reading
Understanding the Securities Class Action Involving Sun Communities

Updated Category News Views 227

Important Announcement for Sun Communities, Inc. Investors In recent developments, the Rosen Law Firm, recognized globally for its advocacy on behalf of investor rights, has initiated a class action lawsuit targeting Sun Communities, Inc. (SUI). This legal action pertains to transactions involving SUI securities that occurred between February 28, 2019, and September 24,...

Continue Reading